Given this risk, we thought we'd take a look at whether Larimar Therapeutics (NASDAQ:LRMR) shareholders should be worried about its cash burn. In this report, we will consider the company's annual ...

JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp ...

Larimar anticipates the dosing of this cohort will be completed by the end of this month. The data from this cohort is expected to be presented during the nomlabofusp program update in September 2025.